

65-252

April 26, 1999

Office of Special Nutritionals (HFS-450) 9434 '99 JUN -2 P1 23
Center for Food Safety and Applied Nutrition
Food and Drug Administration
200 C Street S.W.
Washington, D.C. 20204

RECEIVED
5/24/99

*Advancing the
standard of
scientifically-based
nutrition to sustain
and improve
the quality of life.*



2204 NW Birdsedale
Gresham, OR 97030
(503) 661-5401
(800) 869-9705
(503) 666-4913 FAX
E-mail: info@tyler-inc.com
www.tyler-inc.com

Dear Sir or Madam,

Pursuant to Section 6 of the Dietary Supplement Health and Education Act of 1994, Tyler Encapsulations wishes to notify the Food and Drug Administration that it will within the next 30 days commence to market a dietary supplement which bears statements of nutritional support.

The dietary supplement for which the statements are made is Calcium D-Glucarate. The dietary ingredient that is the subject of the statements is Calcium D-glucarate. The statements of nutritional support are as follows:

1. Calcium D-Glucarate supports detoxification by increasing elimination of toxins via Phase II glucuronidation pathways.
2. Calcium D-glucarate increases net glucuronidation by inhibiting beta-glucuronidase.
3. Calcium D-glucarate exhibits antiproliferative properties in animal studies.

I certify that the information contained in this notice is complete and accurate, and that we have substantiation that these statements are truthful and not misleading.

Sincerely,

Jeremy Appleton
Director of Technical and Regulatory Affairs

LET3626